The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
just now and made BOOM my largest holding.
Given the wording of today's RNS and the current trajetory of the business, at least $45M 2021 revs looks very likely. St current USD to GBP exchange rate, if BOOM were taken over at same revs multiple as Wondery (7.5), we coupd be looking at £15 per share. The longer a t/o can be resisted, the more a suitor will need to pay. An absolutely fantastic sharebto hold and a bulletin board free from rainbow chasers, bullsh** merchants and day traders. Great stuff.
I can't see any major western economy banning BTC being used in purchases for two reasons. First, nobody uses it for purchases anyway. It's like banning the use of cats as toothbrushes. Secons, the people that actually run the western world will be makimg money from BTC and the politicians who pretend to run it won't legislate to hurt the folk who will give them cushy jobs when they step back from public service.
It would be just like the current Govt. to throw billions at LFT's while those available are of limited use and then abandon the scheme as soon as an LFT that really works becomes available. It would not surprise me at all if British AVCT ends up selling its tests everywhere but the UK, due to UK Govt. mismanagement of the LFT programme.
EBITDA profitability reached.
Superb revenue growth.
Record quarterly income.
If first 1/4 reflected across 2021 - a very modest assumpton, given rapid revenue growth - would mean revs of roughly £27.5M for 2021 at curremt exchange rate.
Recent takeover of rival was at 7 x revs.
Same for BOOM equates to SP of approx. £12.50.
SP currently £7.20.
Happy days here and lots of SP upside IMO.
GLA.
I am in this share for the fundamentals and a takeover. The most recent takeover of a similar independent podcaster was at 7 x annual revenue. 7 x currently forecast 2021 BOOM revs equals a share price above £10. As BOOM approaches EBITDA profitbility and its revs continue to increase, so the takeover value increases and the incentive for predators to pounce increases so as to prevent them having to pay even more. I sold at £3 in late Jan and ended up buying back at above £4. Not going to repeat that error. Just my musings. GLA.
For me, the takeaway from today's news is the scale of the endeavour. No single company can fulfil the required demand for national, twice-weekly LFT's.
This is good news for any company which can get a half decent LFT on the market in numbers in the foreseeable future. Any company that can produce a good test in good numbers will do very well. That should, you would expect, include AVCT.
Equally, today's news is good news for PCR test suppliers. They will continue to be the required test for symptomatic cases and will also now have a larger market in confirmatory tests on the back of positive LFT tests.
The Govt said today that 4.2 million LFT's in English schools from 18-24 March returned 4,500 positives - just over 1 in 1,000.
They also said that the false positive rate is "less than 1 in 1,000".
Based on the above disclosures, it is perfectly possible that most of the positives from existing LFT's are false and that the LFT's currently being used in schools are, in fact, pretty useless. If so, AVCT is being set a very low bar to clear in order to be one of the best in class.
Good to see us finish above the placing price today. Patience is needed, but news (or even the anticipation of it for those who are less patient) will be rewarded in due course IMO.
Sheikra, if you want to talk about cryptocurrencoes, do it elsewhere. This is the 4D Pharma board.
more or less. The company has manynirons in the fire. The benefit of NASDAQ listing wil come when there is positive news (or anticipatoon of the likelihood of the same), because that will bring DDDD's liw mxap in comparison to its NASDAQ listed peers into sharp focus. It is simply a wsiting game IMO. You are much more likely to make money in small cap companies by being patient than being the opposite.
Just manages to pick up another £2k worth at 16.2p but needed a fill or kill order to do so.
I can't believe this price to be honest. For anyone with any patience from here, it really does seem like a gift.
As others have stated, the RNS indicates projected streams data revenue of at least £1.5 million in 2022. Makes a mcap of £5-6million after placing and acquisition (at current SP) look really cheap. Still unhappy about timing of last Friday's interview, but have taken the opporyunity to add just now at 0.255p, midway between placing price and issue price of shares going to Krunch.
Of late, this board has become a good case study of the "empty vessels" principle. Filter button now employed.
appeared here this morning, which routinely appear, briefly, on the boards of "hot stocks" talking of multi-bags, etc. They've gone now, presumably with their 10%. None of which affects the fundamentals here, which are great. Now listed on NASSAQ. Still hugely undervalued v peers who have nothing like DDDD's pipeline. Well funded. Lots of news anticipated. For anybody other than day traders, it is all good here IMO. Good luck to all holders.
Great to see two directors lining up to spend £1.44 million on shares. Another big positive sign.
Pork's I agree with much of your analysis. I made a mint (by my standards) on AVCT last year, buying in Feb on the oncology potential and selling in May for a 500%+ profit. Best ever percentage gain on a trade. I am invested here at NCYT at a 720p average and am very confident. Maybe I am risk-averse by the standards of many AIM investors, but I am unwilling to buy anything at an all-time high SP, simply because at all-time highs, good news will trigger sells and bad news will trigger sells. AVCT may be the exception to the rule. Maybe their CV results will be incredible, but I just can't bring myself to buy any share at an ATH, based on hoped-for news, regardless of how incredible the hoped-for news might be. Been burned before doing that and would much rather invest in a company like NCYT which is already raking in huge piles of cash and which has seen its value slide, despite that, to a lowly P/E level. GLA.
IMO is that PCR tests are going to be needed in large numbers for as long as Covid testing is needed. There is potentially one LFT test that may be really reliable - that of AVCT. That's not certain, although initial indications, from.a small sample size, are positive. That test is not on the market yet and will be one of many LFT tests, the rest of which IMO are of patchy efficacy. I suspect that there is going to be an issue of trust with LFT's. I know that if one of my family ever gets a positive LFT result, the first thing I will do is arrange a PCR test. Equally with symptoms and a negative LFT, I will want a PCR. It may seem counterintuitive, but widespread roll out of LFT's will imo be very good for NCYT. I sincerely hope it is an effective way to suppress and detect the virus as, like everyone, I am sick of this. I really think the public will turn to PCR as soon as an LFT result puts them in isolation, eslecially if the LFT positive is returned in the absence of symptoms.